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Background. The chemokine CXCL10 is specifically upregulated during experimental development of plaque with an unstable
phenotype. In this study we evaluated the functional consequences of these findings in mice and humans. Methods and Results. In
ApoE−/− mice, we induced unstable plaque with using a flow-altering device around the carotid artery. From week 1 to 4, mice
were injected with a neutralizing CXCL10 antibody. After 9 weeks, CXCL10 inhibition resulted in a more stable plaque phenotype:
collagen increased by 58% (P = 0.002), smooth muscle cell content increased 2-fold (P = 0.03), while macrophage MHC class
II expression decreased by 50% (P = 0.005). Also, the size of necrotic cores decreased by 41% (P = 0.01). In 106 human carotid
endarterectomy specimens we found that increasing concentrations of CXCL10 strongly associate with an increase in atheromatous
plaque phenotype (ANOVA, P = 0.003), with high macrophage, low smooth muscle cell, and low collagen content. Conclusions.
In the present study we showed that CXCL10 is associated with the development of vulnerable plaque in human and mice. We
conclude that CXCL10 might provide a new lead towards plaque-stabilizing therapy.
1. Introduction
Atherosclerosis is a progressive inflammatory disease of the
arterial vasculature with lesions that may turn unstable,
whichmay lead to lesion rupture. The highmortality of these
ruptures has been associated with atherosclerotic plaques
that display a specific histological phenotype, characterized
by a large pool of lipids and necrotic cell debris covered by
a thin fibrous cap and the presence of inflammatory cells in
the plaque shoulders [1].
Previously, we developed an experimental animal model
in which plaques with stable and unstable characteristics are
simultaneously induced in a single straight arterial segment
[2]. We subsequently identified specific expression profiles of
various chemokine genes in vulnerable plaque development
[3]. In these, the chemokine CXCL10 was specifically
upregulated during the early phase in the development of the
vulnerable plaque segment.
CXCL10 is a member of the CXC family of chemok-
ines. Upon stimulation with interferon-gamma (IFN-γ) it
is expressed by many cell types, for example, monocytes/
macrophages, endothelial cells, fibroblasts, and natural killer
cells [4, 5]. Eﬀects of CXCL10 are mediated by the G-
protein coupled receptor CXCR3, which is known to be
expressed by resting and activated T cells, NK cells, and a
subset of peripheral blood monocytes [5–7]. Furthermore,
CXCL10 plays a variety of roles in inflammatory diseases,
like in the initiation and maintenance of T-helper-1- (Th1-)
polarized immune responses [8, 9], migration of activated T
cells [10], but also of natural killer cells [11], of monocytes
[12, 13] and of smooth muscle cells (SMC) [14].
Despite these compelling findings described in the lit-
erature, in atherosclerosis CXCL10 has been less com-
pletely characterized. In human atherosclerosis, but not in
healthy arteries, endothelial cells, smooth muscle cells, and
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macrophages express CXCL10 [15]. Functional observations
in CXCL10 gene knockout mice indicated that CXCL10
exerts pro-atherogenic eﬀects, probably related to the specific
recruitment and retention of activated Th1 cells and down-
regulation of a regulatory T-cell response [16]. While these
findings indicate that CXCL10 plays a role in atherogenesis,
its eﬀect on plaque composition is unclear. Based on our
previous observations on gene expression in the mouse
model, we hypothesized that CXCL10 mediates development
of vulnerable atherosclerotic plaque. Hence, we assessed
whether CXCL10 plays a critical role in unstable plaque
development by evaluating the eﬀect of antibody-mediated
functional inhibition of CXCL10 on lesion phenotype in
our vulnerable plaque mouse model. To provide evidence
that the findings in the mouse bear relevance for human
atherosclerosis, we also investigated the association between
CXCL10 concentrations and plaque composition in human
carotid endarterectomy lesions.
2. Materials and Methods
2.1. Animals and Surgical Procedures. Apolipoprotein-E defi-
cient mice, 15–20 weeks of age, were obtained from the
Jackson Laboratories (Bar Harbor, ME, USA). They were fed
a high fat, high cholesterol diet consisting of 15% (wt/wt)
cocoa butter and 0.25% cholesterol (wt/wt) (Diet W, Hope
Farms, Woerden, The Netherlands). Two weeks after this diet
was initiated, the mice were instrumented with a shear stress-
altering device around the right common carotid artery
under 2% isoflurane anesthesia, as described previously [2].
Briefly, this device gradually narrows the vessel lumen to
∼70% of its original diameter. As a consequence, shear stress
is lowered upstream of the device, gradually increases inside
the device, and is oscillating just downstream of the device
[17]. After surgery, the mice were kept on the high fat,
high cholesterol diet for the remainder of the experiment.
The device remained in situ for 9 weeks. Intervention and
control groups consisted of at least 10 animals per group.
All animal experiments were approved by the institutional
animal ethical committee and performed in compliance with
institutional and national guidelines.
2.2. CXCL10 Inhibition. Mice were intravenously injected
three times a week in week 2–4 after surgery with an anti-
mouse bioactivity-neutralizing monoclonal CXCL10 anti-
body (MAB466, R&D Systems, Abingdon, United Kingdom)
in a dose of 25 μg in 0.2mL sterile PBS. Untreated cast-
instrumented mice served as control.
2.3. Isolation and Analysis of Murine Tissues. Following
sacrifice, blood was collected and mice were flushed sys-
temically with PBS. Next, the common carotid artery
was isolated, embedded in OCT compound (Tissue-Tek,
Sakura, Japan), and snap-frozen in liquid nitrogen. For
histology, 8 μm cryosections were cut and stained for routine
histology (Hematoxylin-Eosin, HE), lipids (Oil Red O),
collagen (Picrosirius Red), macrophages (anti-CD68, AbD
Serotec, Oxford, UK), macrophage activation (anti-Major
Histocompatibility Complex (MHC) class II, clone M5/114,
ATCC TIB-120), and smooth muscle cells (anti-SMC α-
actin, Sigma-Aldrich, The Netherlands). Subsequently, high-
resolution images were taken using an Olympus BX-40
microscope or a Zeiss LSM5 Meta confocal microscope
(Zeiss Jena, Germany). Collagen stainings were assessed
using crossed circular polarization filters. To calculate lesion
size and cellular content relative to the plaque area, all
images were analyzed after digitalization by automated
image analysis software (Clemex Technologies Inc, Canada)
applying thresholding of the stained areas. Necrotic cores
(defined as hypocellular plaque cavities devoid of collagen,
containing cholesterol clefts) were assessed based on HE and
Picrosirius Red stained sections and measured relative to the
lesion area. Total cholesterol levels were measured in serum
samples by an enzymatic colorimetric method (Cholesterol
E, Wako Diagnostics, USA).
2.4. Endarterectomy Procedures. All patients in this study
were participants of a prospective study aimed at investigat-
ing the predictive value of plaque characteristics for long-
term outcome (Athero-Express), of which the study methods
have been described extensively before [18]. In short, all
patients underwent carotid endarterectomy, during which
arterial wall tissue was obtained. Next, the culprit lesion,
defined as the segment with the largest plaque burden,
was processed for histological examination. In addition to
HE staining, sections were stained for collagen (Picrosirius
Red), SMC (α-actin), and macrophage (CD68) content.
Histological assessment was performed in a semiquantitative
fashion (none, minor, moderate, heavy), on basis of two
independent observers. When results contradicted, a third
independent observer was consulted. Subsequently, plaques
were designated as fibrous (lipids constitute <10% of lesion
surface area), fibroatheromatous (10–40% lipids), or athero-
matous (>40% lipids) based on collagen and HE stainings.
Besides, plaques were also designated as SMC dominant
or macrophage dominant based on the prevailing cell type
obtained from the specific stainings.
A 5mm segment directly adjacent to the culprit lesion
was crushed in liquid nitrogen, and subsequently total pro-
tein was extracted using 1mL of TriPure Isolation Reagent
(Boehringer Mannheim, Germany), according to the manu-
facturer’s protocol. Then, CXCL10 concentration was mea-
sured by Enzyme-Linked Immuno Sorbent Assay (ELISA)
according tomanufacturers instructions (Quantikine human
CXCL10 immunoassay, R&D Systems, Abingdon, United
Kingdom) and blinded from histological and clinical data.
2.5. Statistical Analysis. SPSS (version 15.0, SPSS Inc., USA)
was used for all analyses. To test the diﬀerences between
the treated and the control mice at 9 weeks of cast place-
ment, a student’s t-test was used. When these data had
a non-Gaussian distribution, a nonparametric t-test was
used. For the endarterectomy samples, to compare CXCL10
levels between categorical baseline and plaque morphology
variables, Kruskal-Wallis and Mann-Whitney tests for non-
Gaussian distributed data were used. To investigate the dif-
ferences between continuous baseline variables and CXCL10,
International Journal of Inflammation 3
patients were categorized into quartiles, named 1 through 4
based on increasing CXCL10 concentration. Subsequently,
these quartiles were used to sort all other variables. One-
way ANOVA was used to compare continuous variables. The
quartiles were also used to visualize the relationship between
CXCL10 concentration and plaque morphology. Data are
described as mean± SD or median (Inter Quartile Range) as
appropriate. A P value of <0.05 was considered statistically
significant.
The authors had full access to the data and take
responsibility for its integrity. All authors have read and agree
to the manuscript as written.
3. Results
3.1. Suppression of CXCL10 Bioactivity Inhibits Experimental
Vulnerable Plaque Formation. As we previously found that
CXCL10 is expressed specifically in developing unstable
lesions [3], we investigated if CXCL10 is also functionally
involved in the development of plaque vulnerability using a
mouse model that we developed before [2]. ApoE-deficient
mice, in which a shear stress-altering device was applied,
were injected with a bioactivity-neutralizing antibody during
the onset of plaque formation. As expected, serum total
cholesterol levels did not diﬀer between treated and control
mice (30.13 ± 4.6 versus 29.92 ± 6.7mmol/L, P = 0.92).
Short-term inhibition of CXCL10 did not influence the
extent of plaque development, since we found no diﬀerence
in lesion size between the treated and the control mice after
9 weeks of shear stress alteration. Because macrophage foam
cells are characteristic of atherosclerosis, we measured both
plaque lipid (31.3± 8.0% treated versus 29.5± 7.0% control)
and macrophage content (31.7 ± 7.6% treated versus 27.8 ±
7.0 control; Figure 1(a)), where both remained unchanged
upon CXCL10 inhibition.
To assess plaque vulnerability, we determined the
amount of collagen in the lesions, which is the main stabil-
izing component of the plaque. Interestingly, we found a 57%
increase in the relative amount of collagen in the plaques
following CXCL10 suppression (17.8 ± 6.5% versus 11.3 ±
5.5%, P = 0.002; Figure 1(b)). The amount of plaque
collagen is essentially the result of a balance between collagen
deposition and breakdown. Therefore, the increase in colla-
genmay be the result of decreased breakdown predominantly
by proteinases secreted by activated macrophages. To deter-
mine the extent of immune activation, we measured MHC
class II by immunohistochemistry. The cellular morphology,
location in the plaque and spatial association of MHC class
II staining with macrophage staining by CD68 antibodies in
adjacent sections (Figures 1(a) and 1(c)) strongly suggests
that MHCII-positive cells are the prime cells expressing this
activation marker. We found a 50% reduction in the plaque
MHC class II levels following CXCL10 inhibition (6.3± 3.3%
versus 12.6 ± 7.4%, P = 0.005; Figure 1(c)). In addition,
the amount of SMC, which is known to produce collagen,
nearly doubled in the CXCL10-suppressed group (13.5 ±
8.4% versus 6.3 ± 7.0%, P = 0.03; Figure 1(d)), suggesting
that the diﬀerences in collagen content may be explained by
several factors.
The necrotic core is a hallmark component of the vul-
nerable plaque. To test whether CXCL10 inhibition reduces
necrotic core formation, we analyzed both the number of
necrotic cores in the lesions as well as their relative size.
We found that CXCL10 inhibition resulted in fewer necrotic
cores: 38.9 ± 22.1% versus 57.7 ± 20% of the sections
covering the entire lesion that contained a necrotic core
(P = 0.02). Moreover, also the relative size of the necrotic
cores decreased following antibody treatment from 26.4 ±
11.4% to 15.6 ± 6.1% of the plaque surface area (P = 0.01;
Figure 1(e)).
3.2. Patient Characteristics. For this study endarterectomy
specimens of 106 patients were analyzed. An overview of
the patient characteristics is provided in Table 1. Histological
examples of the lesions are shown in a previous publication
by Verhoeven et al. [18]. The CXCL10 concentration in
the specimens ranged from undetectable to 384.8 pg/mL,
with a median (interquartile range) of 38.34 pg/mL (14–
39 pg/mL). To compare continuous CXCL10 levels to the
categorical variables, patients were categorized into quartiles
(Figure 2). The variables were then tested for changes across
the quartiles. No diﬀerences were found comparing risk
factors for atherosclerotic disease. The use of medication did
not diﬀer significantly between the quartiles.
3.3. High CXCL10 Concentrations Identify Patients with
a More Vulnerable Plaque Phenotype. Several significant
associations were found between plaque composition and
CXCL10 levels. Atheromatous lesions were more prominent
at higher CXCL10 concentrations than those classified as
fibrous (Rank 53 versus 45, P = 0.003). Also, higher CXCL10
concentrations were associated with more macrophage-
dominant plaques (Rank 56 versus 41, P = 0.009), fewer
smooth muscle cells (Rank 39 versus 74, P = 0.001), and
less collagen (Rank 37 versus 63, P = 0.003).
Subsequently, we analyzed the association between
plaque composition and CXCL10 levels, by dividing patients
into quartiles based upon CXCL10 concentration. More
atheromatous lesions were represented in the higher quar-
tiles, while fibrous lesions were more frequently present
in the lower quartiles (Figure 3(a)). Macrophage-dominant
lesions were mostly found in the top quartiles of CXCL10
content, while SMC dominance associated with lower
CXCL10 concentrations (Figure 3(b)). However, no diﬀer-
ences were seen in the macrophage staining between the
quartiles (Figure 4(a)). This paradox was the result of an
inverse relation between smooth muscle cell staining and
increasing CXCL10 concentrations (Figure 4(b)). Addition-
ally, more collagen staining was seen in the plaques in the
lower quartiles (Figure 4(c)).
4. Discussion
This study may be summarized by its two main findings.
First, we showed a functional role of CXCL10 in vulnerable
plaque formation in an experimental mouse model for
unstable atherosclerotic disease. We observed that inhibiting
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Figure 1: Anti-CXCL10 treatment in atherosclerosis susceptible mice results in a change into a more stable lesion phenotype. A flow-altering
device around the common carotid artery induced atherosclerosis in ApoE−/− mice. From week 1 to 4 of lesion development, a bioactivity-
neutralizing anti-CXCL10 antibody was injected. After 9 weeks, lesions were compared to untreated controls by histology. The pictures show
representative histological sections of treated and control mice. All photographs have been made with the same magnification (100x). Scale
bars are provided in (e) and represent 100 μm. Data in bar diagrams are the mean values ± SD of at least 8 sections from at least 10 diﬀerent
animals per group. CXCL10 inhibition resulted in a more stable morphology evidenced by unchanged amounts of lesion macrophages (a),
increased amounts of collagen (b), decreased macrophage activation (c), increased numbers of SMC (d), and reduced necrotic core size (e).
∗P < 0.05, ∗∗P < 0.01. MHC-II: Major Histocompatibility Complex Class II, SMC: smooth muscle cell.
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Table 1: Patient baseline measurements for carotid endarterectomy specimens.
Clinical
characteristics
Total
Quartile of CXCL10 concentration
P value∗
1 2 3 4
CXCL10 pg/mL 38.3 (14–40)† 0–11.3 11.8–18.4 19.3–37.2 37.6–382.6 0.000
Age (years)† 68.4 ± 8.9 66.0 ± 8.0 68.3 ± 10.2 67.7 ± 8.2 71.2 ± 8.5 0.157
Male (%) 73.6 73.1 70.4 66.7 84.6 0.316
Hypertension (%) 71.7 80.0 70.4 66.7 79.2 0.764
Smoker (%) 24.5 30.8 18.5 32.0 19.2 0.476
Symptomatic disease (%) 86.8 84.6 85.2 92.6 84.6 0.762
Statin (%) 56.6 66.7 55.6 55.6 56.0 0.530
β blocker (%) 39.6 37.5 33.3 56.0 41.7 0.321
ACE inhibitor (%) 39.6 42.3 33.3 40.7 42.3 0.881
Serum values†
Total cholesterol (mmol/L) 4.9 ± 1.3 4.8 ± 0.9 5.2 ± 1.3 4.8 ± 1.7 4.6 ± 1.2 0.564
HDL (mmol/L) 1.2 ± 0.4 1.2 ± 0.4 1.4 ± 0.3 1.1 ± 0.3 1.1 ± 0.4 0.156
LDL (mmol/L) 3.0 ± 1.1 2.7 ± 0.8 3.3 ± 1.0 3.2 ± 1.4 2.7 ± 1.0 0.392
Triglycerides (mmol/L) 1.9 ± 0.9 2.3 ± 1.0 1.8 ± 0.8 2.0 ± 1.1 1.7 ± 0.7 0.434
ApoB (mmol/L) 0.9 ± 0.2 0.9 ± 0.2 1.0 ± 0.2 1.0 ± 0.3 0.9 ± 0.3 0.787
Glucose (mmol/L) 6.6 ± 1.9 5.8 ± 0.7 7.0 ± 2.0 7.0 ± 2.3 6.4 ± 1.9 0.129
CRP (mg/mL)
3.40 3.13 2.96 4.81 4.52 0.221
(1.6–7.3) (1.4–5.8) (1.8–5.8) (1.7–9.1) (1.6–7.3)
Baseline data of 106 patients were stratified into four quartiles according to plaque CXCL10 concentration. †Values are represented as mean± SD or median
(Inter Quartile Range) as appropriate. ∗P values based on ANOVA test between CXCL10 quartiles for continuous variables and nonparametric Mann-
Whitney test for categorical variables.
CXCL10 with a bioactivity-neutralizing antibody resulted in
plaques with less macrophage activation, with more SMC
and a subsequent increase in collagen content compared to
controls. A decreased number and size of necrotic cores in
the lesions of the treated animals further substantiated these
findings. This resulted in a lesion phenotype with increased
intrinsic stability.
Second, we found that in human carotid plaques,
CXCL10 levels are associated with lesion morphology. This
is evidenced by an increased number of atheromatous
plaques with increasing CXCL10 concentrations, and by
the association with unstable plaque characteristics, such as
macrophage dominance and reduced presence of smooth
muscle cells and collagen.
Previous studies have shown that inhibition of CXCL10
by antibodies in an intestinal inflammation animal model
is an eﬀective way to inhibit its function [19, 20]. The
findings in those studies have been ascribed to the reduced
amount of Th1 cells that were recruited to the diseased sites
and either reduced production of inflammatory cytokines
[19] or resulted in inflammatory disease exacerbation [20],
depending on the role of T cells in the pathogenesis of the
disease.
The lesion-stabilizing eﬀect we observed by inhibiting
CXCL10 might be explained by a similar mechanism as
described above, as it has been shown before that inhibition
of the CXCL10-CXCR3 pathway decreases the amount of
lesional T cells [16, 21]. Veillard et al. reported that genetic
deletion of CXCR3 in ApoE knockout mice reduced early
lesion formation, which correlated with an increase in
lesional FoxP3-positive regulatory T cells [21]. Recently,
it has been reported that genetic deletion of CXCL10 in
atherosclerosis susceptible mice also resulted in smaller
lesions, which contained fewer CD4+ T cells [16]. Sur-
prisingly, despite the decrease in overall T-cell presence in
the lesions, a higher expression of FoxP3 as well as of the
anti-inflammatory cytokines IL-10 and TGF-β mRNA was
found. This suggests a more prominent role for regulatory
T cells in this model. A similar increase in FoxP3 and TGF-β
expression was found in a study using a peptide antagonizing
CXCR3 in LDL receptor knockout mice, resulting in smaller
lesions in the aortic root and the aorta [22].
A general limitation of our experimental mouse model
is that there are few T cells in the induced lesions after
9 weeks of cast placement, approximately 2–4 per lesion
cross section [3]. As a consequence, we have been unable
to find a diﬀerence in T-cell numbers following CXCL10
inhibition (data not shown). Nevertheless, the reduction in T
cells might have taken place during the early phase of actual
inhibition. We performed measurements at only one time
point, while the presence of T cells in a lesion changes over
time [23]. Also, the eﬀect of small numbers of T cells might
prove to be very strong [24].
The small numbers of T cells do not allow to produce
suﬃciently reliable data to enable making a comparison
with the situation in mice that are deficient in CXCL 10 by
gene targeting. This cannot be solved by mRNA analyses,
as there was no RNA available from the endarterectomy
samples that have been used. Besides facilitating recruitment
of leukocytes, CXCL10 also induces and sustains a dominant
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Figure 2: Distribution of CXCL10measurements from each patient
across quartiles. Atherosclerotic plaques were obtained from 106
patients during carotid endarterectomy. In the plaque segment
directly adjacent to the culprit lesion, the content of the chemokine
CXCL10 was measured by ELISA. Based on these measurements,
patients were divided into one of four quartiles according to the
CXCL10 concentration. Quartile 1 represents the lesions with the
lowest CXCL10 values, whereas quartile 4 contains the highest. This
figure shows the individual measurements for all patients and the
distribution across each quartile of plaque CXCL10. Horizontal bars
represent the median concentration of each quartile.
Th1-type response by increasing the production of IFN-γ,
providing a positive feedback loop [25]. Neutralization of
CXCL10 might therefore result in a decreased concentration
of IFN-γ in the lesions, which is considered a key cytokine
in disease progression [26] and macrophage activation [27].
This notion is in agreement with our findings regarding
macrophage activation status as measured by MHC class II
expression [27], SMC presence [27], and collagen accumula-
tion [28].
An alternative or additional mechanism of plaque mod-
ification by CXCL10 inhibition might be operative as well.
Not only Th1 and NK cells, as major IFN-γ producers, are
responsive to CXCL10, but also plasmacytoid dendritic cells
(PDC) express CXCR3 and are recruited via this receptor
[29]. The numbers of circulating PDC are reduced in
human atherosclerosis, while immunohistochemical analysis
has indicated that they are recruited to advanced plaques
[30, 31]. PDC are known to produce large quantities of
IFN-α upon activation, and this cytokine functions as an
inflammatory amplifier in the atherosclerotic plaque [32].
Additionally, a minor subset of monocytes has been shown
to be recruited via CXCR3 to inflammatory environments [7]
and might thus contribute to plaque instability as well.
Further research is needed to understand the mech-
anisms underlying the eﬀects of CXCL10 inhibition. For
example, apoptosis could have an important role in the
observed diﬀerences in plaque composition and size. It could
be of interest to study the role of SMC in more detail
by staining serial sections for proliferation and apoptosis
on the one hand and alpha actin on the other hand. In
addition, in situ zymography studies could be performed
to get a clearer idea of the possible role of collagenolytic
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Figure 3: Plaque concentrations of CXCL10 are associated with
lesion morphology. Individual values were divided over quartiles
(see Figure 1). By using ANOVA, we tested to see if plaque CXCL10
concentrations associated with lesion morphology. Increasing
plaque concentrations of CXCL10 were indeed associated with an
increase in atheromatous-type lesions (a) and a decrease of SMC
dominant lesions and an increase of macrophage dominant lesions
(b).
activity in the lesions. It would be very interesting to
know more about the role of the proinflammatory cytokine
microenvironment in the plaque in the experiments with
CXCL 10 inhibition. From the present data, we cannot
exclude that by inhibiting CXCL10 we just postponed the
process of the lesion formation and maturation rather than
permanently altering it. For this argument and because of
the ongoing discussion on the quality of animal models
representing human disease states, we also performed a
parallel study in humans.
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Figure 4: Increasing carotid plaque CXCL10 concentrations are
associated with a less fibrous phenotype. Plaque concentrations of
CXCL10 were associated with histological qualities of the lesion
by ANOVA. Staining for macrophages, SMC, or collagen was
quantified as none, minor, moderate, or high. Based on these
qualifications a weighed value for average staining intensity was
calculated (1, none; 2, minor; 3, moderate; 4, heavy staining).
Macrophage staining was not associated with plaque CXCL10 (a),
whereas high plaque concentrations of CXCL10 were associated
with decreasing amounts of smooth muscle cells (SMC) (b), and
decreasing collagen (c).
Mach et al. [15] were the first to associate CXCL10 with
human atherosclerosis, reporting that CXCL10 was expressed
in several stages of the disease. CXCL10 was shown to be
present on the surface of endothelial cells, suggesting a role
in the recruitment and adhesion of CXCR3 positive cells
from the circulation. They also showed broad expression of
CXCL10 by SMC and macrophages throughout the lesion.
Little is known about the eﬀects of CXCL10 on human
atherosclerosis development and clinical outcome. Previous
studies sought to correlate plasma CXCL10 levels with the
occurrence of coronary heart disease (CHD). In a case-
control study it was found that CHD risk was associated with
an increase in serum CXCL10 [33]. A later prospective study
showed that indeed increased levels of CXCL10 exist prior
to CHD, but was not considered an independent risk factor
[34]. Our study is the first one to correlate lesional CXCL10
protein content with plaque morphology in humans and to
be a possible predictor of plaque vulnerability. Obviously,
this cannot be measured directly in living patients, so it
would be of interest to know the correlation between lesional
and systemic levels of CXCL10. There were no plasma
samples available tomeasure the systemic CXCL 10 levels and
correlate them to the lesional levels, so this has to await future
work.
In conclusion, we showed that the chemokine CXCL10
plays a functional role in the destabilization of atherosclerotic
plaques in mice and is specifically upregulated in vulnerable
plaques in humans. Since the experimental data were
paralleled by similar findings in human unstable lesions,
CXCL10 might be regarded as a new lead into understanding
the process of plaque destabilization.
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